Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP2 Effects on Glucose Metabolism in Obesity
NCT06254365Active, not recruiting
- Sponsor
- Gentofte Hospital
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, single-blind trial of liver-expressed antimicrobial peptide 2 in obesity (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Change in hepatic metabolic rate of glucose. Started Feb 2024; status: active, not recruiting.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06254365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254365.